Skip to main navigation
Fulcrum Therapeutics logo
Menu Button

Main Menu

  • About
  • Our Approach
  • Pipeline
    • Publications
  • Therapeutic Focus
    • FSHD
    • SCD
    • Beta-thalassemia
  • Careers
    • Current Openings
    • Faces of Fulcrum
  • Investor Relations
    • News Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
  • Contact

News Releases

News Releases

Feb 26, 2021
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, March 4, 2021 at 8:00 a.m. ET
Feb 26, 2021
Fulcrum Therapeutics Recognizes Rare Disease Day 2021
Feb 19, 2021
Fulcrum Therapeutics to Participate in Upcoming Investor Conferences
Jan 22, 2021
Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Jan 19, 2021
Fulcrum Therapeutics Announces Pricing of Public Offering of Common Stock
Jan 19, 2021
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
Jan 19, 2021
Fulcrum Therapeutics Announces Promotion of Christopher Moxham, Ph.D., to Chief Scientific Officer
Jan 06, 2021
Fulcrum Therapeutics to Participate in the H.C. Wainwright BioConnect 2021 Conference

Investor Tools

Print
Email Page
Email Alerts
IR Contact
Fulcrum Therapeutics logo
  • Privacy Policy
  • EU Privacy Policy
  • Terms of Use
  • Twitter
  • LinkedIn
  • Instagram

Main Menu

  • About
  • Our Approach
  • Pipeline
    • Publications
  • Therapeutic Focus
    • FSHD
    • SCD
    • Beta-thalassemia
  • Careers
    • Current Openings
    • Faces of Fulcrum
  • Investor Relations
    • News Releases
    • Events and Presentations
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Investor FAQs
  • Contact